Factor XIa Tied to Benefit Beyond Stroke Prevention

Published Date: 09 May 2026

Results from the OCEANIC-STROKE trial show that the investigational Factor XIa inhibitor, asundexian, not only reduces the recurrent ischaemic stroke risk, but when they do occur, they are less likely to be disabling or fatal.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Beyond What Is Visible in Myelofibrosis?

2.

MCh in Surgical Oncology: Admission, Medical School, Fees, Qualifications Information

3.

ASCO Future Focus: Follicular Lymphoma: Future Focus from the American Society of Clinical Onology

4.

Fake Cancer Drugs; Let's Talk About Sex; Reducing Cancer-Related Fatigue

5.

In SCLC, Radiotherapy Plus Immunotherapy Ups Fatal Events


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot